PRO 140, with the CAS number 674782-26-4, is a small molecule that functions as a potent and selective antagonist of the CCR5 receptor, which is a chemokine receptor involved in the immune response and is also a co-receptor for HIV entry into cells. This compound has garnered attention in the field of antiviral research, particularly for its potential use in HIV treatment, as it can inhibit the virus from entering and infecting host cells. PRO 140 is characterized by its ability to bind specifically to the CCR5 receptor, blocking the interaction between the receptor and its natural ligands, thereby preventing viral entry. Additionally, it has been studied for its pharmacokinetic properties, including its bioavailability and half-life, which are crucial for its therapeutic application. The compound's safety profile and efficacy in clinical settings are also important aspects of its characterization, as they determine its potential as a treatment option for HIV-infected individuals.

PRO 140

674782-26-4: PRO 140, with the CAS number 674782-26-4, is a small molecule that functions as a potent and selective antagonist of the CCR5 receptor, which is a chemokine receptor involved in the immune response and is also a co-receptor for HIV entry into cells. This compound has garnered attention in the field of antiviral research, particularly for its potential use in HIV treatment, as it can inhibit the virus from entering and infecting host cells. PRO 140 is characterized by its ability to bind specifically to the CCR5 receptor, blocking the interaction between the receptor and its natural ligands, thereby preventing viral entry. Additionally, it has been studied for its pharmacokinetic properties, including its bioavailability and half-life, which are crucial for its therapeutic application. The compound's safety profile and efficacy in clinical settings are also important aspects of its characterization, as they determine its potential as a treatment option for HIV-infected individuals.

<p>Leronlimab (PRO 140), a humanized IgG4 monoclonal antibody, targets CCR5 to combat HIV and cancer.</p>

Leronlimab

<p>A humanized IgG4 anti-CCR5 monoclonal antibody.</p>

CAS 674782-26-4

PRO 140

Leronlimab

Ref: TM-T77059

Leronlimab

Ref: 3D-CLA1516